Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats.

McQueen DS, Bond SM, Smith PJ, Balali-Mood K, Smart D.

Eur J Pharmacol. 2004 May 3;491(2-3):181-9.

PMID:
15140635
2.
3.

Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.

del Carmen García M, Adler-Graschinsky E, Celuch SM.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct;368(4):270-6. Epub 2003 Sep 18.

PMID:
14504685
4.

Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors.

Jerman JC, Gray J, Brough SJ, Ooi L, Owen D, Davis JB, Smart D.

Br J Anaesth. 2002 Dec;89(6):882-7.

5.

Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.

Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-Ruiz JJ.

Eur J Pharmacol. 2001 May 25;420(2-3):123-31.

PMID:
11408034
6.
7.

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V.

Br J Pharmacol. 2001 Oct;134(4):845-52.

8.

The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism.

De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V.

J Biol Chem. 2001 Apr 20;276(16):12856-63. Epub 2001 Jan 26.

9.

Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response.

Hermann H, De Petrocellis L, Bisogno T, Schiano Moriello A, Lutz B, Di Marzo V.

Cell Mol Life Sci. 2003 Mar;60(3):607-16.

PMID:
12737320
10.

Cannabinoid activation of recombinant and endogenous vanilloid receptors.

Ralevic V, Kendall DA, Jerman JC, Middlemiss DN, Smart D.

Eur J Pharmacol. 2001 Jul 27;424(3):211-9.

PMID:
11672565
12.

Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.

de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernández-Ruiz J.

Brain Res. 2004 May 8;1007(1-2):152-9.

PMID:
15064146
14.

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.

Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJ, Brown P, Bridges D, Ledent C, Bifulco M, Rice AS, Di Marzo V, Baker D.

Eur J Pharmacol. 2002 Mar 29;439(1-3):83-92.

PMID:
11937096
16.

Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology.

Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, Cairns W, Hayes PD, Randall AD, Davis JB.

Eur J Pharmacol. 2001 Apr 6;417(1-2):51-8.

PMID:
11301059
17.

Possible mechanisms of cannabinoid-induced antinociception in the spinal cord.

Morisset V, Ahluwalia J, Nagy I, Urban L.

Eur J Pharmacol. 2001 Oct 19;429(1-3):93-100. Review.

PMID:
11698030
18.

Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors.

De Petrocellis L, Davis JB, Di Marzo V.

FEBS Lett. 2001 Oct 12;506(3):253-6.

20.

Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide.

Sprague J, Harrison C, Rowbotham DJ, Smart D, Lambert DG.

Eur J Pharmacol. 2001 Jul 6;423(2-3):121-5.

PMID:
11448475
Items per page

Supplemental Content

Write to the Help Desk